The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO GU 2021

VJOncology has assembled a panel of leading experts, who offer their perspectives on the latest bladder and kidney cancer data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, which was held virtually in February 2021.

In this podcast, Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, is joined by Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, Andrea Apollo, MD, National Cancer Institute, Bethesda, MD, and Thomas Powles, MBBS, MRCP, Barts Cancer Institute, London, UK.

Tune in to learn more about the latest clinical trial data in genitourinary cancer, including updates from EV-301, evaluating enfortumab vedotin versus chemotherapy in patients with urothelial cancer, and CheckMate 274, studying adjuvant nivolumab for high-risk bladder cancer patients. The panel also discuss findings from the POUT trial for perioperative chemotherapy in upper tract urothelial cancer and investigations into combinations of cabozantinib, nivolumab and ipilimumab in all GU tumors. The panel share their insights on these exciting trial updates and debate how these advances will translate into multidisciplinary care for patients with genitourinary cancers.